We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
3.34 | 2.60% | 132.00 | 131.965 | 128.63 | 128.66 | 7,236,513 | 01:00:00 |
By Michael Calia
Merck & Co. said Thursday that a pair of its hepatitis C virus treatments showed a cure rate of 98% in a mid-stage trial, supporting advancement of the study.
The drug maker said it has initiated a Phase 3 trial after analyzing the study results of the 12-week regimen using the treatments, MK-5172 and MK-8742. The company said the study also showed a 94% cure rate for patients receiving those treatments, plus ribavirin.
The company said there were no early discontinuations of the treatment due to adverse effects, nor were any significant abnormalities detected. The most common side effects were fatigue, headache, nausea, diarrhea and insomnia, Merck said.
Merck has taken some hits lately as it contends with patent expirations on lucrative drugs, as well as issues with bringing new products to the marketplace. Last year, the company said it would cut its workforce by 20% over two years, including cutting positions in its research and development operations. The company has also said it would consider shedding some products and businesses.
The company in February said it agreed to collaborate with other drug makers to study its investigational cancer treatment.
Shares of Merck rose 1.8% to $58.10 in recent premarket trading. Through Wednesday's close, the stock was up 14% so far this year.
Write to Michael Calia at michael.calia@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions